Our results indicate that the high expression of METTL3 is related to the high SUVmax in ESCA, and that 18F-FDG PET may help determine the therapeutic strategy for ESCA patients by predicting tumor response to METTL3-targeted therapies. This evidence concerns the gene METTL3 and neoplasm.